| 2001 |
- Yukio Kobayashi becomes chairman and representative director of Taiho Pharmaceutical
- Toru Usami becomes president and representative director of Taiho Pharmaceutical
|
|---|
| 2002 |
- Taiho Pharma U.S.A., Inc. (now Taiho Oncology, Inc.) established in New Jersey in the U.S.
|
|---|
| 2003 |
- Inuyama Plant in Aichi Prefecture starts operations
|
|---|
| 2004 |
- Taiho Pharmaceutical signs a licensing agreement for new antiemetic palonosetron with Helsinn Healthcare SA (Switzerland)
|
|---|
| 2005 |
- Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc. (at the time of the agreement)
|
|---|
| 2007 |
- Annex to the head office completed
- New solid dosage manufacturing plant completed at the Tokushima Plant.
|
|---|
| 2008 |
- Otsuka Holdings established
- Taiho Pharmaceutical of Beijing Co., Ltd., established
|
|---|
| 2009 |
- Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd
|
|---|
| 2011 |
- Taiho Pharma Singapore Pte. Ltd. (now TAIHO PHARMA ASIA PACIFIC PTE. LTD.) Established
|
|---|
| 2012 |
- Masayuki Kobayashi becomes president and representative director
- License agreement for anti-allergy drug bilastine signed with Spain-based Faes Farma S.A.
|
|---|
| 2013 |
- Kitajima Plant completed in Tokushima Prefecture
- Agreement signed on transfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2015 |
- Co-promotion agreement concluded with Meiji Seika Pharma Co., Ltd. for Bilanoa.
|
|---|
| 2016 |
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) completed at the Kitajima Plant
- TAIHO PHARMA CANADA, INC. established in Canada
|
|---|
| 2017 |
- Taiho Pharmaceutical Concludes Option and License Agreement with Arcus Biosciences
- Taiho Pharmaceutical Signs a Co-promotion Agreement with Janssen Pharmaceutical K.K. for Guselkumab, a Human Anti-interleukin (IL)-23 Monoclonal Antibody, in Japan
|
|---|
| 2018 |
- HP building (Highly Potent Pharmaceutical Ingredients) completed at Saitama Site
|
|---|
| 2019 |
- Taiho Innovations, LLC, (now TAIHO INNOVATIONS LTD.) established in Japan
- North American commercialization rights for INQOVI transferred from Otsuka Pharmaceutical Co., Ltd.
- Licensing agreement concluded with Cullinan Pearl Corp., operated by Cullinan Oncology, Inc. (at the time of the agreement), in the United States.
|
|---|
